ablation BCB of confirmed in common 85% of the RF atrial group vs. flutter 65.6% of the using cryoablation group. and 4)The primary RF end-point= energy: The of BCB block was study seen in 15% of the RF group vs. 34.4% of the cryoablation group (P<0.014). 117- 65 2 randomized Vs. Group 2) Typical and atypical N/A 1) TAF: No effect of N/A Preinjcention w/ Mg Pre-injection der C typical groups: placebo atrial flutter IV magnesium on superior for conversion of magnesium 2009 placebo flutter; Group 1) 4 immediately magnesium QTc interval. w/ ibutilide in trypical significantly (206) 52 of IV before improved atrial flutter (p=0.017) enhances the Trial: atypical magnesium administration efficacy of QTc intervals at Preinjection w/ Mg for efficacy of Assess flutter sulfate of a maximum ibutilide for 30 min after conversion w/ ibutilide ibutilide for dose of 2 mg conversion ibutilitde did not no different (p=NS) the w/ of ibutilide (85% w/ differ between Preinjection wih Mg did conversion of fumarate magnesium patients w/ and not affect QT (no typical atrial for vs. 59% w/ w/o ventricular statistic offered) flutter but not placebo, ectopy of atypical w/ p=0.017). atrial flutter. Ibutilide: Atypical atrial flutter: no 117 significant pts (58 difference in w/ and conversion 59 w/o rates between pts receiving magnesium of vs. placebo (48% vs. 65 56%,p=0.189) w/ typical atrial flutter and 52 w/
ablation of common atrial flutter using and RF energy: The study BCB confirmed in 85% of the RF group vs. 65.6% of the cryoablation group. 4)The primary end-point= of BCB block was seen in 15% of the RF group vs. 34.4% of the cryoablation group (P<0.014). C 2009 (206) placebo Trial: Assess w/ for w/ Ibutilide: 117 pts (58 w/ and 59 w/o of 65 w/ typical atrial flutter and 52 w/ 117- 65 typical flutter; 52 atypical flutter 2 randomized groups: Group 1) 4 of IV magnesium sulfate Vs. Group 2) placebo immediately before administration of a maximum dose of 2 mg of ibutilide fumarate Typical and atypical atrial flutter N/A 1) TAF: IV magnesium improved efficacy of ibutilide for conversion (85% w/ magnesium vs. 59% w/ placebo, p=0.017). Atypical atrial flutter: no significant difference in conversion rates between pts receiving magnesium vs. placebo (48% vs. 56%,p=0.189) No effect of magnesium on QTc interval. QTc intervals at 30 min after ibutilitde did not differ between patients w/ and w/o ventricular ectopy N/A Preinjcention w/ Mg superior for conversion w/ ibutilide in trypical atrial flutter (p=0.017) Preinjection w/ Mg for conversion w/ ibutilide no different (p=NS) Preinjection wih Mg did not affect QT (no statistic offered) Pre-injection of magnesium significantly enhances the efficacy of ibutilide for the conversion of typical atrial flutter but not of atypical atrial flutter. der
2015_SVT_Evidence_Tables_Data_Supplement.docx